Participant flow

Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer · Source last updated 2026-05-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Cisplatin: 40 mg/m2 IV (intravenously) weekly for 6 weeks IMRT 6 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy

   id

   FG000

   title

   IMRT 6 Weeks + Cisplatin

2. description

   IMRT 5 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy

   id

   FG001

   title

   IMRT 5 Weeks

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      type

      Protocol Violation

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         158

      2. group Id

         FG001

         num Subjects

         150

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         157

      2. group Id

         FG001

         num Subjects

         149

      type

      Eligible

   3. achievements

      1. group Id

         FG000

         num Subjects

         152

      2. group Id

         FG001

         num Subjects

         147

      comment

      Randomized and eligible participants who started study treatment

      type

      Started study treatment

   4. achievements

      1. group Id

         FG000

         num Subjects

         58

      2. group Id

         FG001

         num Subjects

         57

      comment

      Randomized and eligible with negative post-treatment positron emission tomography (PET) scan

      type

      Negative post-treatment PET

   5. achievements

      1. group Id

         FG000

         num Subjects

         157

      2. group Id

         FG001

         num Subjects

         149

      comment

      Participants contributing data to results are considered to have completed the study

      type

      COMPLETED

   6. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

After first step registration and prior to randomization, patients were tested for p16. Only patients with p16-positive tumors continued on to randomization. In total, 316 patients were enrolled and 308 were randomized.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice